177Lu-FAP-2286联合化疗治疗多转移性骨外尤因肉瘤
本文报告一例23岁男性多转移性骨外尤因肉瘤患者,因无法耐受标准剂量化疗,先接受1周期177Lu-FAP-2286治疗,随后接受2周期减量异环磷酰胺/表柔比星/美司钠化疗。2个月时68Ga-FAP-2286 PET/CT显示肿瘤缩小、示踪剂摄取下降的显著代谢缓解,未观察到不良事件,患者无症状。
要点
- 无法耐受标准剂量化疗的转移性骨外尤因肉瘤患者可考虑177Lu-FAP-2286联合化疗。
- 治疗后2个月68Ga-FAP-2286 PET/CT示肿瘤缩小及示踪剂摄取降低。
- 该例未观察到不良事件,2个月时患者无症状。
核心结论
- 177Lu-FAP-2286联合化疗可能对晚期尤因肉瘤具有临床价值。
研究设计与样本
- 个案报道:1例23岁男性多转移性骨外尤因肉瘤患者,无法耐受标准剂量化疗。
主要发现
- 患者接受1周期177Lu-FAP-2286后行2周期减量异环磷酰胺/表柔比星/美司钠化疗。
- 2个月随访68Ga-FAP-2286 PET/CT示肿瘤缩小、示踪剂摄取降低的显著代谢缓解。
- 未观察到不良事件,患者2个月时无症状。
临床怎么用
- 对无法耐受标准剂量化疗的晚期尤因肉瘤,可探索177Lu-FAP-2286联合减量化疗并以FAP-2286 PET/CT随访疗效。
局限性
- 仅为单个病例,样本量小,疗效与安全性需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 23-year-old man with metastatic extraskeletal Ewing sarcoma, who was unable to tolerate standard-dose chemotherapy, received 1 cycle of 177Lu-FAP-2286, followed by 2 cycles of reduced-dose ifosfamide/epirubicin/mesna chemotherapy. Follow-up 68Ga-FAP-2286 PET/CT at 2 months showed a marked metabolic response with reduced tumor size and tracer uptake. No adverse events were observed. The patient remained symptom-free at 2 months. This case suggests that 177Lu-FAP-2286 combined with chemotherapy may have clinical utility in advanced Ewing sarcoma.
引用
- Mou L, Yao Z, Zheng W, et al. Combined 177Lu-FAP-2286 Therapy and Chemotherapy in Extraskeletal Ewing Sarcoma With Multiple Metastases. Clin Nucl Med. 2026. PMID: 42710080. doi:10.1097/RLU.0000000000006639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。